An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma
An Observational Multicenter Study to Evaluate the Safety and Efficacy of Humacyte's Human Acellular Vessel in a Real World Setting for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma
Sponsor: Humacyte, Inc.
A observational or N/A phase clinical study on Trauma and Trauma Blunt, this trial is completed. The trial is conducted by Humacyte, Inc. and has accumulated 8 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Dec 2024 — Present [monthly]
Completed
-
Sep 2024 — Dec 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Nov 2023 — Mar 2024 [monthly]
Recruiting
▶ Show 3 earlier versions
-
Aug 2023 — Nov 2023 [monthly]
Recruiting
-
Jul 2023 — Aug 2023 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jun 2023 — Jul 2023 [monthly]
Not Yet Recruiting
First recorded
May 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Humacyte, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .